Clinical Trial Update: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) [Phase 3]

View source ↗

Summary

KRYSTAL-4 is a Phase 3 trial evaluating adagrasib plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in previously untreated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• KRAZATI (adagrasib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: RECRUITING